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Abstract
The pulmonary artery (PA) catheter can be a useful tool in the management of patients with cardiogenic shock; however,
there are challenges with the use of this catheter, and clinicians must balance the risks and benefits. In addition, clinicians
must properly interpret data generated from a PA catheter in the context of other data to optimize a patient's hemodynamics.
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Background
The pulmonary artery (PA) catheter can be a useful tool
in the management of patients with cardiogenic shock. It
allows for direct and accurate measurements of hemodynamic
parameters during insertion and serially over time. Serial
observations are very useful for patient monitoring as the
measurements (central venous pressure, right ventricle [RV]
pressures, PA pressures, pulmonary capillary wedge pressure,
saturations) can be used to calculate certain critical data
(cardiac output, vascular resistance, stroke volume, oxygen
delivery, shunt fractions, PA pulsatility index). Beyond this,
PA catheters can even incorporate data simulation to calculate
stress blood volume and other measurements useful in patient
management. Most importantly, data generated from the PA
catheter can provide information on the etiology of shock. It
can detail the type of issue (eg, volume, output, what side) and
what to do next (volume, pressors, mechanical circulatory
support).

Challenges to PA Catheter Use
The challenge with the PA line by itself is that it gives the
clinical team several numbers, and the team then has to

actively integrate and analyze the readings to figure out what
to do. Further, the use of a PA catheter requires time, effort,
and cost—not just with the insertion, but the maintenance of
the catheter. If the catheter is inserted for too long, the patient
can develop a line infection. Data from a PA catheter can be
misinterpreted, misleading, or simply not used. Thus, the
clinical program must regularly educate team members on
how to appropriately use the catheter and the resulting data.
Of note, the information gathered from the PA catheter could
additionally be redundant to other tests (eg, echocardiogram,
central venous pressure measurement alone). Finally,
complications are always a risk.
Despite the challenges, many clinicians caring for patients
with shock insist upon a PA catheter. For each patient, the
team must balance the risks and benefits of the procedure.
With the advent of checklists and their integration into
electronic health records, a team can ensure the PA catheter is
placed in shock patients; however, it is not of value unless the
team goes beyond checking the box and understands what to
do with the data once the catheter is put in to be able to then
manage the patient. Using Medicare data, Ikuta and colleagues
showed that, overall, the use of the PA catheter is declining
over time.1 However, for patients with heart failure, there's an
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inflection point, and the use of catheters started to increase
after 2005.2
A key trial to mention is the ESCAPE trial, which
prospectively gathered data from 433 patients with heart
failure at 26 sites and determined that the use of the PA
catheter was not beneficial in patients who did not need it.2
Importantly, shock patients were not included in the ESCAPE
Trial. Many patients with decompensated heart failure at a
variety of stages that are not that severe can, in fact, be
managed without a PA catheter. The question that remains is,
if the patient is in shock, should you use the catheter?
Cardiogenic shock patients have very little reserve, so if the
wrong decision is made, the patient could decompensate. On
the other hand, inappropriately placed PA catheters could also
lead to complications or suboptimal treatment decisions.

Use of PA Catheter Data
To optimize hemodynamics with a PA catheter, variables
should not be interpreted (or overinterpreted) in isolation.
Serial observations must be interpreted in the context of other
data, and trends are generally more useful than isolated
variables at a single point in time. Integration of measurements
with the clinical situation increases the accuracy of the
assessment. Thus, in a way, the best mantra for shock
management could be summarized as “Keep calm and check,
check, and recheck again on how patients are doing.” If one
does not integrate serial measurements into the clinical
picture, one might end up with a scenario where an agent such
as an inotrope is given to a patient with active ischemia, which
could induce ventricular tachycardia. The blame should not be
on the agent but rather on the team for making the wrong
decision in terms of what to give that patient. Clinicians can
overreact to numbers, and that overreaction can result in
unfavorable outcomes.

Clinical Studies
Studying patients with severe cardiogenic shock is
difficult. However, when an invasive therapy is used in the
sickest patients, and a benefit is still seen in observational
studies of that therapy, that is a powerful outcome. Studies of
the sickest populations usually show worse outcomes because
the patients were so sick to begin with. Even if it is
observational data, beneficial outcomes in these sick
populations are rare. Thus, any benefit signal from
observational studies in severely sick populations should be
further explored in randomized trials. An excellent example is
from the Cardiogenic Shock Working Group which observed
that PA catheter use was associated with lower mortality rates
in patients with cardiogenic shock.3
Another study compared PA catheter-based assessments of
volume optimization and cardiac index to clinical judgment
and found that clinical assessments had low accuracy across
all training levels.4 Thus, clinical teams need to understand the
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importance of using objective data derived from helpful tools,
like a PA catheter. PA catheter measurements can also help
the team determine the ideal device selection5 and volume
optimization.6 Similarly, both sides of the heart must be
assessed to determine the best treatment, as a significant
proportion of patients have biventricular congestion. 7
Emerging data has shown how PA catheter measurements can
be used to identify RV dysfunction.8 Ultimately, PA catheter
assessments have been useful in determining device weaning
protocols.9 While the PA catheter measurements cannot be
used alone, they have been shown to be a valuable tool in the
clinical toolbox.
Randomized trials of PA catheters in cardiogenic shock are
currently being planned by the Cardiogenic Shock Working
Group. However, the proposed PAC-CS Trial has the potential
for failure if it is not done right; just placing the PA catheter
alone is unlikely to be associated with improved outcomes.
Specific guidance is needed to detail what should be done after
the PA catheter is placed. Optimization and regulation of
monitoring the readings from the catheter are vital for the
success of the study.

History of the Swan Catheter
I had the privilege of hearing James Forrester present a
talk on the development of the Swan catheter at the
Transcatheter Cardiovascular Therapeutics meeting in 2019.10
The following story is excerpted and paraphrased from his
talk, which to me was awe-inspiring.
“Dr. Jeremy Swan was inspired by watching sailboats in
the ocean off the coast of California. He hypothesized that a
balloon-tipped catheter could enable a device to go into the
PA or other vessel. As a favor, folks from Edwards
Lifesciences used an infant feeding tube with a balloon and
gave it to Swan to test, and the first animal catheterization by
Diamond and Forrester was completed in 1969. They put the
catheter into the venous system and saw an unusual waveform.
In fact, the catheter had traversed the right heart and was
advanced into the PA. As today’s institutional review board
processes were not in place, they sterilized the catheter and
then used it in a patient admitted to the medical intensive care
unit. Unfortunately, once the catheter was placed, the patient
had a horrific run of ventricular tachycardia that was induced
by the catheter tip flailing wildly within the RV. A later
modification to move the balloon on the tip of the catheter
increased the safety of this catheter. Likewise, today as
clinicians work with really sick patients, it always behooves
us to think about how the placement of a PA catheter could
cause complications.
Dr. Willie Ganz was 49 years old and abandoned all his
worldly possessions and fled communism. Philanthropy
enabled his journey to the United States, and through
serendipity, the unknown lab researcher developed a way to
measure cardiac output through thermistors in an animal
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laboratory. Through collaboration with Dr. Swan and the team
that had developed the PA catheter, the Swan-Ganz catheter
was born.”
In some ways, this is how we must take care of our sick
patients; every one with individual expertise and experiences
must come together to manage the patients with an
individualized treatment plan.
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